Literature DB >> 30602120

Acute Flaccid Myelitis Associated with Enterovirus D68 in Children, Argentina, 2016.

Carolina M Carballo, Marcela García Erro, Nora Sordelli, Gabriel Vazquez, Alicia S Mistchenko, Claudia Cejas, Manlio Rodriguez, Daniel M Cisterna, Maria Cecilia Freire, Maria M Contrini, Eduardo L Lopez.   

Abstract

After a 2014 outbreak of severe respiratory illness caused by enterovirus D68 in the United States, sporadic cases of acute flaccid myelitis have been reported worldwide. We describe a cluster of acute flaccid myelitis cases in Argentina in 2016, adding data to the evidence of association between enterovirus D68 and this polio-like illness.

Entities:  

Keywords:  Argentina; EV-D68; acute flaccid myelitis; children; enterovirus; infectious disease outbreaks; myelitis; viruses

Mesh:

Substances:

Year:  2019        PMID: 30602120      PMCID: PMC6390768          DOI: 10.3201/eid2503.170897

Source DB:  PubMed          Journal:  Emerg Infect Dis        ISSN: 1080-6040            Impact factor:   6.883


We report a cluster of acute flaccid myelitis (AFM) cases in Buenos Aires, Argentina, in 2016. AFM was defined as acute flaccid paralysis (AFP) with magnetic resonance imaging (MRI) showing lesions predominantly affecting the gray matter of the spinal cord (). We prospectively studied all patients with AFP who were admitted to Hospital de Niños “Ricardo Gutiérrez” in Buenos Aires during April 24–August 24, 2016, under the Argentine National Surveillance Acute Flaccid Paralysis Program for poliovirus as part of the World Health Organization AFP Program in the Americas. We obtained fecal samples or rectal swab specimens, serum samples, nasopharyngeal swab specimens, and cerebrospinal fluid (CSF) samples. Fecal samples were tested at the National Reference Center for the Argentine National Surveillance Acute Flaccid Paralysis Program for enterovirus, including wild-type and vaccine-derived poliovirus. We screened clinical samples for enterovirus D68 (EV-D68) using a panrhinovirus and enterovirus nested PCR of enterovirus targeting the 5′ untranslated region (). We purified the amplified products and prepared them for Sanger sequencing. We performed BLAST searches (https://blast.ncbi.nlm.nih.gov/Blast.cgi) of GenBank sequences to identify which picornavirus was present. We obtained viral protein 1 partial sequences as previously described (). In addition, we studied a wide panel of viruses (parainfluenza virus 1, 2, and 3; influenza A/B; respiratory syncytial virus; adenovirus; metapneumovirus; rhinovirus; varicella zoster virus; herpes simplex virus; cytomegalovirus) by reverse transcription PCR (RT-PCR) and studied bacteria by culture. We performed MRI and electromyography for all patients. Fourteen children were admitted with AFP during April–August 2016. Six were confirmed to have AFM by case definition; the other 8 had alternative diagnoses, including Guillain-Barré syndrome (), influenza virus myositis (), encephalitis by echovirus (in 1 child with Down syndrome), acute transient hip synovitis (), and transverse myelitis (). Patientsclinical, demographic, and outcome findings are shown in Table 1, diagnostic findings in Table 2.
Table 1

Demographics, neurologic symptoms, and clinical outcomes for patients with acute flaccid myelitis, Argentina, 2016

FeaturePatient 1Patient 2Patient 3Patient 4Patient 5Patient 6
Age, mo/sex34/M15/F35/M60/F12/F60/F
History of asthma
No
No
No
Yes
Yes
Yes
Preceding illness
FeverNoYesYesYesYesNo
URTIYesYesYesYesYesYes
Gastrointestinal symptoms
No
No
Yes
No
No
No
Neurologic symptoms
Limb, back, or neck painYesYesYesYesYesYes
Arm weaknessYes (bilateral)Yes (right)NoYes (left)Yes (bilateral)Yes (bilateral)
Leg weaknessYes (bilateral)Yes
(progressive,
asymmetric, bilateral)Yes (left progressive to bilateral, asymmetric)Yes (progressive, asymmetric, bilateral)Yes (bilateral)Yes (bilateral)
Neck weaknessYesYesNoYesYesYes
Facial weaknessNoNoNoYesNoYes
Sensitivity involvementNoNoNoNoNoNo
Mental status involvementNoNoNoNoNoNo
Other neurologic deficits
Bulbar weakness
No
No
Left VII cranial nerve palsy
No
Bilateral VII cranial nerve palsy; bulbar weakness; tetraparesis
Severity of disease
ICU care; mechanical ventilation; tracheostomy; feeding support
Weakness
Weakness
ICU care; noninvasive positive pressure ventilation; feeding support
Progressive asymmetric 4- limb weakness
ICU care; mechanical ventilation; tracheostomy;
feeding support
Outcome/sequelaePersistent weakness; feet atrophy; equinus left foot; chronic noninvasive ventilation supportPartial recovery of weakness
Atrophy of left footRecovery of right leg weakness;
equinus left footPersistent leg left paralysis; 2 cm atrophy in left quadricepsPersistent left arm paralysis and left leg weaknessPersistent leg paralysis and arm weakness; noninvasive ventilation support
Duration of hospitalization6 mo14 d10 d46 d8 d4 mo

*ICU, intensive care unit; URTI, upper respiratory tract infection.

Table 2

Diagnostic findings in patients with acute flaccid myelitis, Argentina, 2016

Laboratory testsPatient 1Patient 2Patient 3Patient 4Patient 5Patient 6
Cerebrospinal fluid findings
Leukocytes/mm3 (% mononuclear cells)195 (85)4 (100)23 (84)130 (96)40 (70)16 (54)
Glucose, mg/dL, reference range 40–70535860555776
Protein, mg/dL, reference range 15–50417033344134
Albuminocytological dissociation
No
Yes
No
No
No
No
Virologic findings
Enterovirus-D68YesYesYesYesNoNo
Nontypable enterovirus
No
No
No
No
No
Yes
Type of positive specimen
Nasopharyngeal aspirateYesYesYesYesNoYes
FecesNoYesNoYesNoNo
Cerebrospinal fluid
No
No
No
No
No
No
Time from prodromal illness to specimen collection5 d30 d13 d6 d25 d3 d
*ICU, intensive care unit; URTI, upper respiratory tract infection. In 4 (66.7%) of 6 patients, we confirmed EV-D68 infection by nested RT-PCR. In 1 patient, enterovirus was detected but not typed; in 1 patient, no agent was detected. All patients had distinctive neuroimaging changes. We followed confirmed AFM cases for 6 months to assess clinical improvement. The median age of patients with AFM was 3.9 (range 1–5) years; 4 (66.7%) of the 6 were female, and 3 (50%) had a history of asthma. All patients had prodromal signs or symptoms before onset of neurologic symptoms: 100% had upper respiratory tract infection (URTI); 4 (66.7%) had fever; and 1 (16.7%) had vomiting and abdominal pain. Neurologic symptoms appeared 1–11 (median 2) days after URTI symptoms. Results of hematology and chemistry analysis were normal for 5 (83%) patients. Patient 1 had leukocytosis (leukocytes 18,000 cells/mm3, with 82% neutrophils) and elevated levels of alanine aminotransferase (103 IU/L [reference 10–43 IU/L]), aspartate aminotransferase (97 IU/L [reference 10–35 IU/L]), and creatine kinase (6,591 IU/L [reference 24–170 IU/L]). During follow-up, patient 1 showed an increased creatine kinase level that could not be related to enterovirus infection. All confirmed AFM case-patients showed T2 gray matter hyperintensity within the spinal cord on MRI. Electromyography showed early signs of denervation and low motor neuron function in all 5 patients in whom the test could be done. Specimen collection was performed 9.5 (range 3–30) days after URTI symptoms started and 7.5 (range 1–18) days after onset of neurologic symptoms. We identified enterovirus using nested RT-PCR of nasopharyngeal samples in 5 (83%) of 6 patients; 4 (80%) of 5 were typed as EV-D68, but in 1 patient (20%) the viral load was too low for typing. We identified EV-D68 in 2 (33%) of 6 fecal specimens. We performed molecular characterization of EV-D68 strains based on phylogenetic analyses of a partial VP1 genomic region (Figure).
Figure

Molecular characterization of enterovirus D68 strains from Argentina, 2016, compared with reference strains from GenBank. Tree based on phylogenetic analyses of partial viral protein 1 genomic region (nucleotide positions 2554–2799, corresponding to the Fermon strain). Bold indicates strains detected in this study (GenBank accession nos. MF445419–20). We generated trees using the neighbor-joining method, as implemented in MEGA 6 software (http://www.megasoftware.net). Bootstrap values from 1,000 replicates are shown at the nodes. The trees were rooted with the prototype strain Fermon (GenBank accession no. AY426531). Scale bar indicates nucleotide substitutions per site.

Molecular characterization of enterovirus D68 strains from Argentina, 2016, compared with reference strains from GenBank. Tree based on phylogenetic analyses of partial viral protein 1 genomic region (nucleotide positions 2554–2799, corresponding to the Fermon strain). Bold indicates strains detected in this study (GenBank accession nos. MF445419–20). We generated trees using the neighbor-joining method, as implemented in MEGA 6 software (http://www.megasoftware.net). Bootstrap values from 1,000 replicates are shown at the nodes. The trees were rooted with the prototype strain Fermon (GenBank accession no. AY426531). Scale bar indicates nucleotide substitutions per site. Results of nested RT-PCR for enterovirus were negative for all CSF samples; results of the respiratory virus panel were negative for all patients. Neither bacteria nor fungus were isolated in blood or CSF samples. Serum PCR to identify herpes simplex virus, varicella zoster virus, and cytomegalovirus also yielded negative results. Intravenous immunoglobulin was empirically infused in 5 (83%) patients; 2 (33%) received systemic corticosteroids. Three patients required intensive care unit admission. All patients had neurologic sequelae: persisting palsy in >1 limbs and atrophy of muscles with a shortening of limbs. Two patients required chronic noninvasive ventilatory support during 6 months of follow-up. No patients died.

Conclusions

AFM has been associated with different etiologic agents (). EV-D68 is a nonpolio enterovirus characterized by affinity for α2–6-linked sialic acids typically found in the upper respiratory tract, making the respiratory tract the preferred target for EV-D68 replication, unlike most enteroviruses, which replicate in the gut (,). Although there is no definitive evidence of causality between EV-D68 and AFM, since the 2014 EV-D68 respiratory outbreak in North America, AFM cases possibly associated with EV-D68 have been reported in the United States, Canada, Australia, Norway, Great Britain, and France (,). We report a cluster of AFM associated with EV-D68 in Argentina; another institution in Argentina (Hospital Garrahan) has also reported a case series of AFM (,). The cluster in this report occurred over a 3-month period, during the 2016 autumn–winter season, which is the typical enterovirus season in Buenos Aires. Clinical and neurologic findings were similar to those of cases reported in other countries, including URTI preceding the neurologic features (,,). Patients were admitted with asymmetric, acute, and progressive weakness of limbs; areflexia; and muscle pain. These symptoms have been reported as polio-like syndrome; however, testing and MRI should be performed for multiple viruses, including enteroviruses and EV-D68, to detect distinctive spinal cord lesions. No sensory sensitivity involvement was observed. Two patients had cranial nerve dysfunction. Laboratory findings were similar to those previously described, including CSF abnormalities (,,). Different hypotheses to explain difficulties in isolation of EV-D68 have been reported (). It is possible that most of the nasopharyngeal specimens in previous studies and in our cluster were taken after 7 days of URTI, when the viral load is usually low, as reported by Imamura et al. (). In our case series, enterovirus was identified in respiratory secretions in 5 (83.3%) of 6 patients, even though specimen collection was performed >7 days (mean 9 days) after AFM onset (in 1 patient, viral load was too low for genotyping). The negative nasopharyngeal specimen was collected at 18 days after onset. Isolation of EV-D68 in fecal samples is uncommon because the virus is both heat and acid labile (). However, in 2 (33.3%) of our 6 patients, EV-D68 was identified in fecal samples. Reported rates of CSF detection of known neurotropic enteroviruses, such as polioviruses and enterovirus A71, are as low as 0%–5%, although viruses could be detected in brain or spinal cord tissue (,). A recent mouse model of AFM caused by EV-D68 showed that EV-D68 infects anterior horn motor neurons, resulting in motor neuron death (). In our series, CSF samples tested negative for EV-D68 and other pathogens. No specific treatment for EV-D68 AFM is available; the US Centers for Disease Control and Prevention recommends only support measures (,). Zhang et al. demonstrated that commercial immunoglobulin contained high levels of neutralizing antibodies against EV-D68 strains during the 2014 outbreak in the United States (). No vaccines are available. EV-D68 belonging to subclade B3 was identified in our cluster by molecular sequencing. This subclade was associated with EV-D68 circulation in the United States and Europe in 2016 (). We show a cluster of AFM associated with EV-D68 in Argentina. Our findings contribute to global evidence of EV-D68 as a possible cause of localized polio-like illness.
  12 in total

1.  A fatal central nervous system enterovirus 68 infection.

Authors:  Justin D Kreuter; Arti Barnes; James E McCarthy; Joseph D Schwartzman; M Steven Oberste; C Harker Rhodes; John F Modlin; Peter F Wright
Journal:  Arch Pathol Lab Med       Date:  2011-06       Impact factor: 5.534

Review 2.  2014 outbreak of enterovirus D68 in North America.

Authors:  Kevin Messacar; Mark J Abzug; Samuel R Dominguez
Journal:  J Med Virol       Date:  2015-11-04       Impact factor: 2.327

3.  In Vitro Efficacy of Antiviral Compounds against Enterovirus D68.

Authors:  Eric Rhoden; Mingyu Zhang; W Allan Nix; M Steven Oberste
Journal:  Antimicrob Agents Chemother       Date:  2015-09-14       Impact factor: 5.191

4.  Enterovirus D68 infection in a cluster of children with acute flaccid myelitis, Buenos Aires, Argentina, 2016.

Authors:  Victor Ruggieri; Maria Ivana Paz; María Gabriela Peretti; Carlos Rugilo; Rosa Bologna; Cecilia Freire; Silvana Vergel; Andrea Savransky
Journal:  Eur J Paediatr Neurol       Date:  2017-07-19       Impact factor: 3.140

5.  Neutralization of Enterovirus D68 isolated from the 2014 US outbreak by commercial intravenous immune globulin products.

Authors:  Yiting Zhang; Deborah D Moore; W Allan Nix; M Steven Oberste; William C Weldon
Journal:  J Clin Virol       Date:  2015-06-19       Impact factor: 3.168

6.  Unusual increase of cases of myelitis in a pediatric hospital in Argentina.

Authors:  Guadalupe Pérez; María T Rosanova; María C Freire; María I Paz; Silvina Ruvinsky; Carlos Rugilo; Víctor Ruggieri; Daniel Cisterna; Soledad Martiren; Cristina Lema; Andrea Savransky; Soledad González; Leila Martínez; Diana Viale; Rosa Bologna
Journal:  Arch Argent Pediatr       Date:  2017-08-01       Impact factor: 0.635

7.  Two different PCR assays to detect enteroviral RNA in CSF samples from patients with acute aseptic meningitis.

Authors:  I Casas; P E Klapper; G M Cleator; J E Echevarría; A Tenorio; J M Echevarría
Journal:  J Med Virol       Date:  1995-12       Impact factor: 2.327

8.  Antigenic and receptor binding properties of enterovirus 68.

Authors:  Tadatsugu Imamura; Michiko Okamoto; Shin-ichi Nakakita; Akira Suzuki; Mariko Saito; Raita Tamaki; Socorro Lupisan; Chandra Nath Roy; Hiroaki Hiramatsu; Kan-etsu Sugawara; Katsumi Mizuta; Yoko Matsuzaki; Yasuo Suzuki; Hitoshi Oshitani
Journal:  J Virol       Date:  2013-12-26       Impact factor: 5.103

9.  Enterovirus D68 Subclade B3 Strain Circulating and Causing an Outbreak in the United States in 2016.

Authors:  Guiqing Wang; Jian Zhuge; Weihua Huang; Sheila M Nolan; Victoria L Gilrane; Changhong Yin; Nevenka Dimitrova; John T Fallon
Journal:  Sci Rep       Date:  2017-04-28       Impact factor: 4.379

10.  A mouse model of paralytic myelitis caused by enterovirus D68.

Authors:  Alison M Hixon; Guixia Yu; J Smith Leser; Shigeo Yagi; Penny Clarke; Charles Y Chiu; Kenneth L Tyler
Journal:  PLoS Pathog       Date:  2017-02-23       Impact factor: 6.823

View more
  12 in total

1.  Human Enterovirus Diversity by Next-Generation Sequencing Analysis in Urban Sewage Samples From Buenos Aires Metropolitan Area, Argentina: A Retrospective Study.

Authors:  A Lizasoain; D Mir; M Victoria; M E Barrios; M D Blanco-Fernández; N Rodríguez-Osorio; S Nates; D Cisterna; V A Mbayed; R Colina
Journal:  Food Environ Virol       Date:  2021-03-06       Impact factor: 2.778

Review 2.  Acute flaccid myelitis: cause, diagnosis, and management.

Authors:  Olwen C Murphy; Kevin Messacar; Leslie Benson; Riley Bove; Jessica L Carpenter; Thomas Crawford; Janet Dean; Roberta DeBiasi; Jay Desai; Matthew J Elrick; Raquel Farias-Moeller; Grace Y Gombolay; Benjamin Greenberg; Matthew Harmelink; Sue Hong; Sarah E Hopkins; Joyce Oleszek; Catherine Otten; Cristina L Sadowsky; Teri L Schreiner; Kiran T Thakur; Keith Van Haren; Carolina M Carballo; Pin Fee Chong; Amary Fall; Vykuntaraju K Gowda; Jelte Helfferich; Ryutaro Kira; Ming Lim; Eduardo L Lopez; Elizabeth M Wells; E Ann Yeh; Carlos A Pardo
Journal:  Lancet       Date:  2020-12-23       Impact factor: 79.321

3.  Acute Flaccid Myelitis in Children in Zhejiang Province, China.

Authors:  Liming Gong; Yilong Wang; Weiqing Zhang; Chen Chen; Xinghui Yang; Lu Xu; Congying Zhao; Lihua Jiang; Zhefeng Yuan; Zhezhi Xia; Peifang Jiang; Qiong Ge; Juying Yan; Yi Sun; Yin Chen; Zhengyan Zhao; Yanjun Zhang; Feng Gao
Journal:  Front Neurol       Date:  2020-05-22       Impact factor: 4.003

Review 4.  Understanding Enterovirus D68-Induced Neurologic Disease: A Basic Science Review.

Authors:  Alison M Hixon; Joshua Frost; Michael J Rudy; Kevin Messacar; Penny Clarke; Kenneth L Tyler
Journal:  Viruses       Date:  2019-09-04       Impact factor: 5.048

5.  Enterovirus D68 Subclade B3 Circulation in Senegal, 2016: Detection from Influenza-like Illness and Acute Flaccid Paralysis Surveillance.

Authors:  Amary Fall; Ndack Ndiaye; Mamadou Malado Jallow; Mamadou Aliou Barry; Cheikh Saad Bou Touré; Ousmane Kebe; Davy Evrard Kiori; Sara Sy; Mohamed Dia; Déborah Goudiaby; Kader Ndiaye; Mbayame Ndiaye Niang; Ndongo Dia
Journal:  Sci Rep       Date:  2019-09-25       Impact factor: 4.379

6.  Mapping Attenuation Determinants in Enterovirus-D68.

Authors:  Ming Te Yeh; Sara Capponi; Adam Catching; Simone Bianco; Raul Andino
Journal:  Viruses       Date:  2020-08-08       Impact factor: 5.048

7.  Enterovirus D68 Subclade B3 in Children with Acute Flaccid Paralysis in West Africa, 2016.

Authors:  Amary Fall; Ndack Ndiaye; Kevin Messacar; Ousmane Kebe; Mamadou Malado Jallow; Hamid Harouna; Davy Evrard Kiori; Sara Sy; Déborah Goudiaby; Mohamed Dia; Mbayame Ndiaye Niang; Kader Ndiaye; Ndongo Dia
Journal:  Emerg Infect Dis       Date:  2020-09       Impact factor: 6.883

8.  Enterovirus D68 in a 6-year-old acute flaccid myelitis case in China, 2018: a case report.

Authors:  Xiaoli Wang; Pengfei Zhang; Jie Li; Yanhui Chu; Zheng Li; Yang Yang; Fu Li; Shujuan Cui; Da Huo; Yu Wang; Quanyi Wang
Journal:  BMC Infect Dis       Date:  2020-02-11       Impact factor: 3.090

9.  Enhanced Enterovirus D68 Replication in Neuroblastoma Cells Is Associated with a Cell Culture-Adaptive Amino Acid Substitution in VP1.

Authors:  Syriam Sooksawasdi Na Ayudhya; Adam Meijer; Lisa Bauer; Bas Oude Munnink; Carmen Embregts; Lonneke Leijten; Jurre Y Siegers; Brigitta M Laksono; Frank van Kuppeveld; Thijs Kuiken; Corine Geurts-van Kessel; Debby van Riel
Journal:  mSphere       Date:  2020-11-04       Impact factor: 4.389

10.  Caspase-3 inhibitor inhibits enterovirus D68 production.

Authors:  Wenbo Huo; Jinghua Yu; Chunyu Liu; Ting Wu; Yue Wang; Xiangling Meng; Fengmei Song; Shuxia Zhang; Ying Su; Yumeng Liu; Jinming Liu; Xiaoyan Yu; Shucheng Hua
Journal:  J Microbiol       Date:  2020-09-01       Impact factor: 3.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.